Covid vaccine reinforcements called on the FDA Chief: no data

The FDA chief has questioned whether the agency will approve and authorize the COVID-19 vaccine for winter.

In August 2024, the United States Drug and Food Administration approved the updated Vaccine of Arnt Covid to protect against current variants, and also approved an updated Novavax vaccine.

However, the FDA Commissioner, Dr. Marty Makary, has expressed doubts about whether that is necessary for the 2025-2026 season.

The risk of dementia could immerse yourself with a common vaccine, it suggests a study

“We are taking a look. I can’t comment on any particular application. As you know, we have a lot of applications for those reinforcement shots,” Makary told News on Tuesday, as The Outlet reported.

“I think there is a data vacuum. And I think, instead of allowing this void to fill out opinions, I would like to see some good data,” he added.

Makary also mentioned a “public trusted problem” about Covid’s reinforcements, and noted that many health workers chose them not to receive them last season.

Flu vaccine linked to higher infections, says early research

The FDA chief has also expressed concern about the lack of data that support the NOVAVAX COVID vaccine, asking for more studies on its effectiveness before approved.

“The great study of Novavax 2020-2021 excluded people with natural immunity to Covid. Today, there is an extensive immunity from the population, and the big question is, does it provide a benefit?” He said in an interview with Inside Medicine on Tuesday.

“Without a study on the new formulation and product, we cannot give an honest and evidence -based response to that question.”

Novavax published an update on its FDA application website for an additional clinical trial.

Click here to get the News application

“It is my general feeling, not with this particular product, which I cannot discuss in depth, but with drugs in general, that we need to know if they work today to recommend them,” Makary told News on Tuesday.

Click here to register in our health newsletter

The centers for disease control and prevention (CDC) have also been considering reducing recommendations for generalized COVID vaccines from 2025-2026.

In an April report, the agency presented three options for COVID reinforcements: maintain the “universal vaccine policy” for all 60 years old, to recommend them only for groups with a high risk of serious COVID diseases, or to use recommendations based on the risk of up to 64 years of age and then change to universal recommendations at 65 years.

The main risk factors for serious diseases include elderly, underlying medical conditions and pregnancy, CDC declared.

For more health articles, visit www.Newsnews.com/health

Those who work in medical care or who live in long -term care centers have a greater risk of exposure.